The low bioavailability of zanamivir may be the major reason why reduction of antibody rise was not observed in the systematic review of zanamivir

The low bioavailability of zanamivir may be the major reason why reduction of antibody rise was not observed in the systematic review of zanamivir.[9] However, if zanamivir is administered at a high dose or for an extended period, or if the patient is very susceptible, inhaled zanamivir might reach a concentration high enough to reduce… Continue reading The low bioavailability of zanamivir may be the major reason why reduction of antibody rise was not observed in the systematic review of zanamivir

Published
Categorized as XIAP